Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
Why Teva’s new tardive dyskinesia data matters for shareholders
Teva Pharmaceutical Industries (NYSE:TEVA) has put its neuroscience work in the spotlight by releasing new real world data from the IMPACT-TD Registry at the 2026 American Psychiatric Association meeting.
The registry, described as the largest tardive dyskinesia study to date, focuses on how the condition affects adults with mood disorders and how quickly they receive a formal diagnosis. For investors, it adds fresh information around an area that connects directly to Teva’s existing TD treatment franchise.
See our latest analysis for Teva Pharmaceutical Industries.
Teva’s latest IMPACT TD data arrives alongside solid recent price strength, with a 1 year total shareholder return of 110.49% and a 3 year total shareholder return of about 3.9x. The year to date share price return of 14.12% suggests momentum has carried into 2026.
If you are assessing how neuroscience focused companies like Teva fit into your portfolio, this can be a good moment to scan the market for other healthcare related AI opportunities using the 37 healthcare AI stocks
With Teva shares up sharply over 1 year and trading about 43% below an estimated intrinsic value, the key question is whether the current price still undershoots the TD and neuroscience story or whether the market is already factoring in future growth.
Most Popular Narrative: 12.3% Undervalued
The most followed valuation narrative currently pegs Teva’s fair value at $40.27 per share versus a last close of $35.32. This frames today’s price as a discount that hinges on how its neuroscience and broader R&D story plays out.
Teva’s strategic focus and rapid execution on expanding its branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late-stage pipeline targeting large patient populations, are expected to drive higher-margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.
Curious what has to happen in Teva’s income statement to back up that higher fair value? The narrative leans heavily on earnings quality, margin mix, and a richer profit multiple. The real surprise is how modest top line assumptions can still support a premium valuation if those pieces fall into place.
Result: Fair Value of $40.27 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
